 |
At the core of Nutrition 21, lies the belief that high quality science and ground-breaking technology can lead to the development of superior products. The company’s scientific platform is based upon our ability to create patentable products that have enhanced absorption and bioavailability to produce safe and clinically efficacious results.
Learn
More
Nutrition 21, Inc.
4 Manhattanville Road
Purchase, NY 10577
Phone: 914-701-4500
|
|
|
 |
Nutrition 21’s Assets Acquired by an Investment Group
led by Messrs. Phillip and Michael Satow
The assets of Nutrition 21 have been acquired by an
investment group led by Phillip and Michael Satow. The
Company will continue to operate as Nutrition 21.
Michael Satow will serve as President and Chief Executive
Officer and Phillip Satow as Chairman of the Board. Phillip
and Michael together have almost 50 years of healthcare
experience. Most recently, they founded and built JDS
Pharmaceuticals, LLC (“JDS”), a specialty pharmaceutical
company focused on the psychiatric and women’s health
markets. JDS was sold in 2007 to Noven for $125 million.
Prior to JDS, Phillip was Executive Vice President of Forest
Laboratories, Inc. and President of Forest Pharmaceuticals
as well as a member of the Forest board of directors.
Phillip also served in senior positions at Pfizer and Carter
Wallace. He has served on the boards of directors of public
companies, including Forest Laboratories, Inc. , Crucell
Inc., Eyetech, Inc., and Noven. Prior to JDS, Michael
founded and/or served as CEO of several venture backed
companies as well as practicing as an attorney for five
years. Michael currently sits on several private companies
and non-profit boards.
Michael Satow commented, “We are very excited about the
acquisition of Nutrition 21’s assets. As CEO, I am
committing the Company to continuing the highest standards
of quality and customer service. We intend to invest in and
grow this business as well expand the Company’s range of
offerings.”
Phillip Satow stated that, “The nutraceutical and functional
food sectors are undergoing significant regulatory and
market change. Our knowledge of the healthcare space,
combined with the deep experience of Nutrition 21’s
personnel will position us well for growth going forward.”
For further information, please contact Bill Levi at
blevi@nutrition21.com …
- - - - - - - - - - - - -
Leveraging its biotechnology heritage, Nutrition
21 is pioneering an effort to use patented technology,
pharmaceutical research and strategic marketing and distribution
partnerships to build its position in therapeutic markets. The
Company is targeting specific disease states and age related
health care concerns through its patented and proprietary
ingredients. The disease states and therapeutic areas include
obesity/pre-diabetes, metabolic syndrome, diabetes,
cardiovascular health, arthritis, mood disorders, cognitive
function, digestive health, and immune system health.
Nutrition 21 relies on well designed preclinical and clinical
trials as key elements of its discovery, product development,
and marketing strategies. The Company’s objective is to
translate its scientific findings into trusted brands recognized
for their measurable contribution to improving health and
reducing cost of care. The Company earns the trust of consumers
with endorsements from healthcare professionals and by getting
our products adopted as a standard therapy recommended by
doctors and health care professionals.
Different from most biotechnology or pharmaceutical companies,
the Company is primarily focused on developing products that are
marketed under the Dietary Supplement Health and Education Act
(DSHEA) regulatory pathway. The Food and Drug Administration’s
(FDA) regulations for the supplement category enable companies
to bring products to market in less time and with less cost than
is required for FDA drug approval. Different from most
nutritional supplement companies, clinical substantiation is a
requirement for our product development program.
Armed with clinical evidence that promises to reveal remarkable,
clinically measurable effects of its products in therapeutic
approaches to epidemic diseases, Nutrition 21 enjoys the
following unique competitive advantages:
• An established base business that supports a robust clinical
research and business development effort;
• An expertise in identifying and patenting nutrition therapies
addressing overlapping health markets that affect as many as 75
percent of US adults;
• A history of successfully patenting its innovations and
enforcing its patents;
• Research alliances with leading universities, research
institutes and scientists;
• A proven track record in leveraging clinical outcomes to build
consumer and trade awareness for its nutrition products through
public relations;
• Close working relationships with many of the major nutritional
product marketers and manufacturers, and finished product
retailers in the US;
• A robust product development pipeline
Nutrition 21 is fully committed to the responsible marketing of
dietary supplements. The company not only uses pharmaceutical
research standards to establish the safety and efficacy of the
products it markets, but also maintains that commitment through
a rigorous manufacturing and quality assurance programs.
|
|
 |
|
|
|
